Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
| Revenue (TTM) | $63.70B |
| Gross Profit (TTM) | $47.59B |
| EBITDA | $25.38B |
| Operating Margin | 27.90% |
| Return on Equity | 5.01% |
| Return on Assets | 5.78% |
| Revenue/Share (TTM) | $11.19 |
| Book Value | $14.95 |
| Price-to-Book | 1.89 |
| Price-to-Sales (TTM) | 2.63 |
| EV/Revenue | 3.33 |
| EV/EBITDA | 15.72 |
| Quarterly Earnings Growth (YoY) | -10.10% |
| Quarterly Revenue Growth (YoY) | 2.60% |
| Shares Outstanding | $5.70B |
| Float | $5.69B |
| % Insiders | 0.10% |
| % Institutions | 69.06% |
Volatility is currently expanding
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
A rotation may be taking place, out of tech stocks and into healthcare. Pfizer is one of the more attractive-looking healthcare stocks to own right now, based on its valuation and dividend payments.
Soda, toothpaste, phone service, electricity, and prescription drugs all share one trait: people keep buying them when the economy turns ugly.
Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.
A yield above 6% looks like a retirement lifeline until the math behind it starts to crack.
Most retirees chase yield and end up with dividends that vanish the moment the economy wobbles.
The drugmaker faces significant patent cliffs this year and next. But it also has a robust pipeline of new drugs in development.
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PFE and any ticker you trade — then tracks every position and per-strategy win rate.
